Dimethylformamide → (R)-2-(1-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)-1H-imidazol-4-yl)acetonitrile

HRID 44832

Reaction equation

HRID 44832 reaction equation
[NH:1]1[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]1.CN[C@@H]1[CH2:16][CH2:15][CH2:14][CH2:13][C@H:12]1[NH:17][CH3:18].C([O-])([O-])=O.[Cs+].[Cs+].[CH3:25][N:26]([CH:28]=[O:29])[CH3:27]>>[CH:12]1([N:17]2[C:18]3[N:3]=[C:2]([N:1]4[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]4)[N:1]=[CH:5][C:25]=3[N:26]([CH3:27])[C:28](=[O:29])[C@H:4]2[CH2:6][CH3:7])[CH2:13][CH2:14][CH2:15][CH2:16]1

Participants

5

Conditions

Temperature
110 °C

Procedure

A mixture of intermediate B (150 mg, 0.509 mmol), 2-(1H-imidazol-4-yl)acetonitrile (1.01 mmol, 2 equivalents, 108 mg), Cut (0.1 equivalents, 0.0509 mmol, 10 mg), trans-1,2 bis(methylamino)cyclohexane (14 mg, 0.102 mmol) and Cs2CO3 (1.01 mmol, 331 mg) in DMF (1 mL) was purged with nitrogen and was subsequently heated in a sealed vial at 110° C. for 18 h. The reaction was diluted with ethyl acetate, filtered through Celite and evaporated. The residue was purified by reverse phase preparative HPLC and lyophilized to give the title compound (185 mg). 1H NMR (CDCl3) δ: 8.66 (s, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 4.31-4.37 (m, 2H), 3.91 (s, 2H), 3.38 (s, 3H), 1.70-2.13 (m, 10H), and 0.93 ppm (t, J=7.4 Hz, 3H); LCMS: 366.1 m/z (M+H)+; ret. Time: 3.444 min (Analytical Method A).

Workup

  1. customwas purged with nitrogen
  2. additionThe reaction was diluted with ethyl acetate
  3. filtrationfiltered through Celite
  4. customevaporated
  5. customThe residue was purified by reverse phase preparative HPLC

Sources & evidence

ORD record
ord-8cc89f87399b4b3e82cd973d4487ed03
Source dataset
uspto-grants-2013_09
Patent number
US08541418B2

Linked notes

Loading…